Researchers have discovered a mechanism underlying the development of treatment resistance to proteasome inhibitors in multiple myeloma. Surprisingly, the mechanism also was linked to a…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Cancer Treatment Centers of America (CTCA) recently began enrolling patients with cancer for the clinical trial study TAPUR — Targeted Agent and Profiling Utilization Registry.
Early treatment with a combination of anti-cancer drugs in patients with smoldering myeloma, who are at high risk of developing multiple myeloma, may avoid disease…
The monoclonal antibody Darxalex (daratumumab) was recently approved by the U.S. Food and Drug Administration (FDA), in combination with either Revlimid (lenalidomide) and dexamethasone, or…
Aduro Biotech recently presented positive preclinical data showing that its monoclonal antibody, BION-1301, may successfully inhibit multiple myeloma tumor growth, survival, and resistance to other…
The results of a new clinical trial suggest that two extension treatments that are frequently added to standard therapy care in patients with multiple…
